BEARINGPOINT
24.11.2022 13:16:34 CET | Business Wire | Press release
Management and technology consultancy BearingPoint’s latest study suggests mobility decisions will be very different by 2030. The study, “Destination 2030, Who’s in the driving seat for the future of mobility?” identified three trends that will drive mobility in the coming years:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005066/en/
Destination 2030 - who’s in the driving seat for the future of mobility? (Graphic: Business Wire)
1.) every journey will become a personalized experience
2.) climate neutrality will be non-negotiable – from the cradle to the grave
3.) users will consume services rather than own vehicles.
“It will be a radically different mobility ecosystem that will affect automotive manufacturers, transportation providers, and even energy suppliers as well as tech and insurance companies. What changes is how services are provided and consumed, and these industries must start preparing now. The growth of personalized mobility, mobility as a service and the push towards carbon-neutrality will all profoundly impact the way we think about travel. We’ll control our travel experiences in a new way, and this will impact our relationship with car brands, potentially weakening their ownership of us as customers,” said Dr. Stefan Penthin, global leader Automotive, Industrial Equipment & Manufacturing at BearingPoint.
Remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility
The study drew from BearingPoint’s internal research, the views of clients across all industry sectors and input from the consultancy’s sector and technology leaders. The study says remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility and the direction and pace of change.
“87% of the survey participants believe they will commute less frequently to work and 81% said they will take significantly fewer business trips compared to 2019, and if this trend continues, it will impact investment in infrastructure. The increased costs associated with developing new mobility infrastructure cannot be passed on entirely to the end user. Legislation may also need to be implemented to achieve the right infrastructure to support electric vehicles. Licensing and enforcement will shift focus from the individual to the provider,” said Andrew Montgomery, global leader Government and Public Sector at BearingPoint.
Three trends that will drive mobility in the coming years
The study sees every journey becoming a personalized experience. Public transportation will shift toward individual mobility, with schedules dictated by consumer needs, rather than predefined as with traditional public transportation. This will lead to more user-centric offerings, making traveling time more productive.
Climate neutrality will be non-negotiable, according to the study, which points to 80% of manufactured engines being green by 2030. Investment will increase in zero-impact modes and related infrastructure, particularly those that promote well-being, such as walking and cycling. And half of the participants (49%) say that they would sacrifice vehicle ownership to reduce their environmental footprint by 2030.
As users will consume services rather than own vehicles, they will switch to on-demand services rather than owning an underutilized vehicle. The services and software will be more important to the general consumer than the physical vehicle and brand, as software platforms will orchestrate the entire journey. 81% of participants point out that they will prefer to use one single app/platform for ordering and billing all their mobility-related services. The study also sees new entrants as constructors, not disruptors.
For more details, please read the full article here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
